menu
    • menu
    [{"orgOrder":0,"company":"Lotus Pharmaceutical","sponsor":"Klinge Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lotus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Lotus Pharmaceutical \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Lotus Pharmaceutical \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Lotus Pharmaceutical","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Lotus Pharmaceutical","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Lotus Pharmaceutical \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Lotus Pharmaceutical \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Lotus Pharmaceutical","sponsor":"Corium","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lotus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Lotus Pharmaceutical \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Lotus Pharmaceutical \/ Lotus Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Actavis Inc

    Menu

    Actavis Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Peptide Process CMC
                            Not Confirmed

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : $125.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LENZ and Lotus Sign License Deal for LNZ100 in Korea and Southeast Asia

                            Details : Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 09, 2025

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : $125.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Peptide Process CMC
                            Not Confirmed

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Recipient : Klinge Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lotus Becomes Strategic Partner for the Commercialization of Biosimilar Ahzantive

                            Details : Through the collaboration, Lotus will lead the commercialization of Ahzantive (Aflibercept) in the designated regions, a biosimilar candidate to Eylea.

                            Product Name : Ahzantive

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 05, 2025

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Recipient : Klinge Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Peptide Process CMC
                            Not Confirmed

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Donepezil

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Corium

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Trea...

                            Details : Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval p...

                            Product Name : Adlarity

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 08, 2023

                            Lead Product(s) : Donepezil

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Corium

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Forest Laboratories

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Tris Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            May 21, 2019

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Tris Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Actavis Inc

                            Ireland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 17, 2019

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Forest Laboratories

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Tris Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 20, 2019

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Tris Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Actavis Inc

                            Ireland arrow
                            Peptide Process CMC
                            Not Confirmed

                            08

                            Actavis Inc

                            Ireland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 17, 2018

                            Lead Product(s) : Nepafenac

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Actavis Inc

                            Ireland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Endpoint Study of Ivermectin 0.5% Lotion

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 04, 2017

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Actavis Inc

                            Ireland arrow
                            Peptide Process CMC
                            Not Confirmed